Dendreon Reimbursement Support:

We’ve got you covered

  • Dendreon now offers PROvide, a commercial co-pay program specific to patients with coverage from a private commercial health plan
  • PROvide supports eligible patients by covering any combination of
    cost—co-pays, co-insurance, or deductible costs—to a maximum of $6000
    over the 3 PROVENGE treatments

Dendreon ON Call is Now ONline!

  • Available 24/7 online, Dendreon ON Call offers a quick and convenient way to enroll patients, receive and monitor benefit verification information, view patient status and case history, send secure messages, and more.

Dendreon Reimbursement Support:

We've got you covered

  • All Medicare Administrative Contractor regions cover PROVENGE based on the FDA-approved label
  • Plans representing approximately 99% of patients with private insurance cover PROVENGE based on the FDA-approved label

NCD and Q-Code

In 2011, CMS1 issued a National Coverage Determination (NCD) and Q-code for PROVENGE that simplify patient coverage criteria and expedite electronic billing and payment.

All Medicare Administrative Contractors cover PROVENGE, and reimburse for administration2, based on the FDA-approved label, per the NCD.

Download the latest guide for updated coding and billing instructions, with annotated forms to help minimize errors that can delay reimbursement:

Start PROVENGE Therapy

To start PROVENGE—and access patient assistance and scheduling resources—enroll your patients through Dendreon ON Call.

Patient Assistance

Good News: 75% of patients receiving PROVENGE are expected to have minimal to $0 out of pocket costs. But for those with no coverage for PROVENGE, or who need help covering costs, Dendreon supports several patient assistance options, including:


1 Centers for Medicare and Medicaid Services
2 Administration reimbursement is retroactive for dates of service on or after June 30, 2011


PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.


PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.

In controlled clinical trials, serious adverse events reported in the PROVENGE group include acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. Severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.

The most common adverse events (incidence ≥ 15%) reported in the PROVENGE group are chills, fatigue, fever, back pain, nausea, joint ache, and headache.

Please see the Full Prescribing Information.

Full Prescribing Information